NK-mediated immunotherapy and uses thereof

The present invention refers to a method for the production of activated CD3^–CD56⁺ NK cells, activated CD3^–CD56 NK⁺ cells obtainable with said method, their use, in particular for the treatment of a tumor, preferably a hepatocellular carcinoma (HCC), for use in the treatment and/or prevention of an HCV infection, for use in the treatment and/or prevention of a post-liver transplant HCV reinfection, or for use for prevention of a post-liver transplant HCC recurrence. The invention also concerns pharmaceutical compositions including said activated CD3 ^–CD56⁺ NK cells.